CONMED (US:CNMD) ZACKS·2025-07-31 00:01Core Insights - Conmed reported revenue of $342.35 million for the quarter ended June 2025, reflecting a 3.1% increase year-over-year and a surprise of +0.81% over the Zacks Consensus Estimate of $339.59 million [1] - The company's EPS for the quarter was $1.15, up from $0.98 in the same quarter last year, with an EPS surprise of +1.77% compared to the consensus estimate of $1.13 [1] Revenue Breakdown - Domestic revenue reached $190.6 million, exceeding the average estimate of $186.19 million, marking a year-over-year increase of +2.8% [4] - International revenue was reported at $151.7 million, slightly below the estimated $153.68 million, but still showing a +3.4% increase year-over-year [4] - Net sales in Orthopedic Surgery amounted to $140.7 million, surpassing the average estimate of $139.41 million, with a year-over-year change of +0.9% [4] - Capital Products net sales were $44.5 million, falling short of the $50.63 million estimate, representing a significant year-over-year decline of -15.7% [4] - Single-use Products generated $297.8 million in net sales, exceeding the average estimate of $289.24 million, with a year-over-year increase of +6.6% [4] - General Surgery net sales were reported at $201.6 million, slightly above the estimated $200.46 million, reflecting a +4.7% change compared to the previous year [4] Stock Performance - Conmed's shares have returned -7% over the past month, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]